Q-omics provides the consensus-scored NDUFS6 profile across patient tissues and cancer cell-line models. NDUFS6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFS6 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, NDUFS6 protein abundance shows 19,289 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, LIHC, and GBM as cancer lineages where NDUFS6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFS6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFS6 survival associations across molecular data types. NDUFS6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFS6 RNA expression–survival associations across cancer types. High NDUFS6 expression shows unfavorable associations in UVM, KICH, ACC, BRCA, LIHC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFS6 RNA expression.
This table summarizes NDUFS6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFS6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFS6 shows higher tumor expression in LIHC, LUAD, LUSC, UCEC, HNSC and STAD. The LIHC box plot shows higher NDUFS6 RNA expression in tumor versus normal tissue (log2 FC = +1.216, t-test p < 0.001).
This table shows molecular features associated with NDUFS6 in patient tissues and cancer cell lines. In patient samples, NDUFS6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFS6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
